RAMP1 and migraine disorder: The transdermal delivery of niosomal ZOL (TPFsp60/6−1:1) showed significantly enhanced management of migraine pain symptoms and markers, decreased RAMP-1, NPTX-2, and CB-1/MAPK gene expression reflecting improved efficacy and brain receptor delivery.